- Home
- DJT vs GHRS Comparison
DJT vs GHRS Comparison
Compare DJT & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DJT | GHRS |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DJT | GHRS |
|---|---|---|
| Price | $8.35 | $28.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | ★ 4.8M | 378.2K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,682,600.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.76 | N/A |
| 52 Week Low | $6.96 | $11.83 |
| 52 Week High | $18.97 | $31.44 |
Technical Indicators
Market Signals| Indicator | DJT | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.84 | 50.80 |
| Support Level | $8.10 | $25.66 |
| Resistance Level | $8.77 | $28.96 |
| Average True Range (ATR) | 0.63 | 1.48 |
| MACD | -0.22 | -0.12 |
| Stochastic Oscillator | 7.88 | 37.10 |
Price Performance
Historical ComparisonAbout DJT Trump Media & Technology Group Corp.
Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.